A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Phase of Trial: Phase I
Latest Information Update: 11 Aug 2018
At a glance
- Drugs JNJ 63723283 (Primary) ; Niraparib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Janssen Research & Development
- 31 Jul 2018 Planned End Date changed from 31 Mar 2021 to 31 Dec 2020.
- 25 May 2018 Planned End Date changed from 31 Dec 2020 to 31 Mar 2021.
- 29 Mar 2018 Status changed from not yet recruiting to recruiting.